Source - LSE Regulatory
RNS Number : 1544O
Dr. Martens PLC
05 February 2021
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.

 

5 February 2021

 

 

Dr. Martens plc

 

Exercise of Over-allotment Option

 

Further to its announcement on 29 January 2021 relating to its initial public offering (the "Offer"), Dr. Martens plc ("Dr. Martens") announces that Goldman Sachs International, acting as the stabilising manager, has today given notice to exercise the over-allotment option (the "Over-allotment Option") granted by IngreLux S.àr.l., a Luxembourg company owned by funds advised by Permira, in respect of 52,500,005 ordinary shares in Dr. Martens at the offer price of 370 pence each.

 

Giving effect to the exercise of the Over-allotment Option, the final total size of the Offer is £1.489 billion (402,500,040 ordinary shares), representing in total 40.3 per cent. of the ordinary shares in Dr. Martens.

 

Enquiries:

 



Finsbury (public relations adviser to Dr. Martens)

 

·      Rollo Head / James Leviton / Nidaa Lone

DrMartens@Finsbury.com

+44 (0)207 251 3801



 

Important Legal Information

 

The information contained in this announcement is for background purposes only and does not purport to be full or complete, nor does this announcement constitute or form part of any invitation or inducement to engage in investment activity. No reliance may be placed by any person for any purpose on the information contained in this announcement or its accuracy, fairness or completeness. The contents of this announcement are not to be construed as legal, financial or tax advice.

This announcement and the information contained herein is not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any State of the United States and the District of Columbia), Australia, Canada, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for, or otherwise invest in, securities to any person in any jurisdiction, including the United States (including its territories and possessions, any State of the United States and the District of Columbia), Australia, Canada, Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered, sold or resold in the United States unless registered under the United States Securities Act of 1933, as amended (the "Securities Act") or in a transaction exempt from, or not subject to, the registration requirements of the Securities Act. The securities referred to herein have not been, and will not be, registered under the Securities Act or under the applicable securities laws of Australia, Canada or Japan. Subject to certain exceptions, the Shares referred to herein may not be offered, sold or resold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. There was no, and will be no, public offer of the securities referred to herein in the United States, Australia, Canada, Japan, or elsewhere.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEANASEFPFEEA
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.